Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer

This study has been terminated.
(The enrollment is too slow.)
Information provided by (Responsible Party):
Xichun Hu, Fudan University Identifier:
First received: May 6, 2014
Last updated: April 26, 2016
Last verified: April 2016
Comparing Docetaxel Plus Fulvestrant With Docetaxel in Patients With Metastatic Breast Cancer

Condition Intervention Phase
Metastatic Breast Cancer
Drug: Docetaxel
Drug: Fulvestrant
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective Single-center Randomized Phase 3 Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Postmenopausal, Hormone-receptor Positive and HER2-negative Metastatic Breast Cancer

Resource links provided by NLM:

Further study details as provided by Fudan University:

Primary Outcome Measures:
  • Progression Free Survival [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Overall Response Rate [ Time Frame: 6 Weeks ] [ Designated as safety issue: Yes ]
  • Overall Survival [ Time Frame: 6 Weeks ] [ Designated as safety issue: Yes ]

Enrollment: 22
Study Start Date: April 2014
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Docetaxel Plus Fulvestrant

Docetaxel:75mg/m2 D2 every 21 days

Fulvestrant:500mg D1, D15, D29, D57, every 28 days later

Drug: Docetaxel
75mg/m2 D2 every 21 days
Other Name: Taxotere
Drug: Fulvestrant
500mg D1, D15, D29, D57, every 28 days later
Other Name: Faslodex
Active Comparator: Docetaxel
Docetaxel:75mg/m2 D2 every 21 days
Drug: Docetaxel
75mg/m2 D2 every 21 days
Other Name: Taxotere

Detailed Description:
Comparing Docetaxel Plus Fulvestrant With Docetaxel in Postmenopausal, Hormone-receptor Positive and HER2-negative Metastatic Breast Cancer

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Postmenopausal female between 18 and 70 years old
  • ECOG performance status of ≤ 1
  • Life expectancy more than 3 months
  • Histologically confirmed metastatic breast cancer
  • ER and&or PR pqositive, HER2-negative
  • Disease progression during adjuvant or first-line endocrine therapy, or endocrine naive but unsuitable for endocrine therapy alone
  • No pretreated chemotherapy for metastatic disease
  • Have at least one target lesion according to RECIST 1.1
  • No therapy (chemotherapy, endocrine therapy, target therapy and operation) within 4 weeks before enrollment
  • Hemoglobin ≥ 90 g/L, Absolute Neutrophil Count ≥ 1.5×10^9/L, Platelet Count ≥ 75×10^9/L, Serum Bilirubin ≤ 1.5×ULN, ALT and AST ≤ 1.5×ULN, Serum Creatinine ≤ 1×ULN, Endogenous Creatinine Clearance>50ml/min

Exclusion Criteria:

  • Pregnant or lactating women
  • Evidence of CNS metastasis
  • Seriously uncontrolled infection
  • History of another malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix
  • Pretreated with Fulvestrant
  • Pretreated with two or more lines of endocrine therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02137083

Fudan University Cancer Hospital
Shanghai, China, 200032
Sponsors and Collaborators
Fudan University
Principal Investigator: Xichun Hu, MD, PhD Fudan University
  More Information

Responsible Party: Xichun Hu, Vice Director of department of medical oncology, Fudan University Identifier: NCT02137083     History of Changes
Other Study ID Numbers: Fudan BR2014-13 
Study First Received: May 6, 2014
Last Updated: April 26, 2016
Health Authority: China: Ethics Committee

Keywords provided by Fudan University:
Endocrine therapy

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Hormonal
Estrogen Receptor Antagonists
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Hormones processed this record on October 28, 2016